Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

initiation of chronic kidney replacement therapy (dialysis or kidney transplantation), and death from kidney disease or death from CV disease. Findings showed treatment with semaglutide reduced ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...

“Chronic kidney disease is very serious and common in ... establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most broadly indicated glucagon-like peptide-1 receptor agonist ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...

"Everyone was randomized to semaglutide or a placebo, all had chronic kidney disease or specific criteria and all had type 2 diabetes," says Dr. Pratley. In addition to taking Ozempic, patients ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and Ozempic, could have “an antidepressant effect,” suggesting ...